01 Automation and Robotics Integration in Hts Integrating robotics and automation in HTS systems is revolutionizing the market by improving efficiency and accuracy in screening processes. Automation allows for high-speed testing, reduces human error, and enhances experiment reproducibility. This is driven by the need for faster and more reliable results in drug discovery. For instance, according to the National Institutes of Health (NIH) reports. High-throughput screening accelerates antibacterial drug discovery by rapidly testing extensive molecule collections for bioactivity. Over 50% of current antibiotics are derived from natural products
02 Ai and Machine Learning for Data Analysis in Hts AI and ML in HTS are changing how data is analyzed and decisions are made. These advanced technologies allow for identifying subtle patterns and correlations within massive datasets that otherwise would be hard or impossible for a human to find. By applying AI and ML, researchers can predict biological outcomes with higher accuracy, prioritize compounds, and optimize screening processes, saving time and resources. For instance, according to the U.S. Food and Drug Administration (FDA), Increasing the use of AI in the lifecycle of the drug, CDER points to the considerable increase in submissions driven by AI for drug application. These encompassed nonclinical, clinical, postmarketing, and manufacturing phases that reflect the ever-growing impact of AI across multiple therapeutic areas.
May 2026 Araceli Biosciences launched Endeavor® Live Cell, an ultra-high-throughput live-cell imaging platform designed for AI-driven drug discovery, enabling rapid kinetic imaging across 1,536-well screening plates to support large-scale high-throughput screening workflows.
February 2026 SCIEX introduced compatibility between its Echo® MS+ System and the ZenoTOF 8600 System, expanding high-throughput screening capabilities with enhanced sensitivity for label-free mass spectrometry assays used in pharmaceutical drug discovery.
January 2026 Umicore Precious Metals Chemistry acquired high-throughput screening technologies, specialty ligand capabilities, and related equipment from Solvias, expanding its HTS service portfolio for pharmaceutical and fine chemical customers.
June 2025 Sartorius launched the iQue® 5 HTS Platform, a next-generation high-throughput screening cytometer featuring expanded multiplexing capability, enhanced automation, and continuous high-throughput operation for drug discovery and cell therapy research.